Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, July 1, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, June 30, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Uy Ear Initiated (ARQT) at Strong Buy and Held Target at $58 on, Jun 30th, 2021
Uy Ear of Mizuho, Initiated "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy and Held Target at $58 on, Jun 30th, 2021.
Uy has made no other calls on ARQT in the last 4 months.
There is 1 other peer that has a rating on ARQT. Out of the 1 peers that are also analyzing ARQT, 0 agree with Uy's Rating of Hold.
This is the rating of the analyst that currently disagrees with Uy
- David Lebowitz of "Morgan Stanley" Initiated at Buy and Held Target at $52 on, Thursday, May 27th, 2021
